+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating clazakizumab, a drug administered by subcutaneous injection, to study its effect on reducing high-sensitivity C-reactive protein hsCRP, a marker of inflammation, in adults with elevated hsCRP and increased risk for cardiovascular events. This phase 2b, randomized, double-blind, placebo-controlled study focuses on adults with established atherosclerotic cardiovascular disease or other risk factors such as obesity, type 2 diabetes, hypertension, or chronic kidney disease. The study aims to understand how clazakizumab compares to placebo in lowering inflammation related to cardiovascular risk. Participants will receive one of several doses of clazakizumab or a placebo via subcutaneous injection. The treatment period involves dosing and monitoring up to 32 weeks, with the primary outcome measured at 12 weeks and additional assessments at 24 weeks. The study includes a double-blind design where neither participants nor researchers know who receives the active drug or placebo. Pharmacokinetics of clazakizumab will also be evaluated during the trial. Throughout the approximately 9-month participation, participants will undergo blood tests to measure hsCRP levels at baseline and multiple follow-up points, including week 12 and week 24. Researchers will assess the percent change in hsCRP to evaluate inflammation changes. Safety and drug concentration will be monitored regularly. Participants will have scheduled visits for study drug administration and assessments, ensuring careful observation during the study period.

Age: 18Years +All GendersPhase 2
46 locations
P

Actively Recruiting

Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.

Age: 18Years +All GendersPhase 2
221 locations
P

Actively Recruiting

Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.

Age: 18Years +All GendersPhase 3
804 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.

Age: 18Years +All GendersPhase 4
149 locations
E

Actively Recruiting

Researchers are studying the safety and tolerability of switching from semaglutide to a new combined treatment called CagriSema in adults with type 2 diabetes. This phase 3 clinical trial evaluates three different dosing schedules of CagriSema in people who have been taking semaglutide once weekly. The goal is to understand how well participants tolerate this switch and monitor any side effects during the treatment period. Participants who have been treated with once-weekly semaglutide will switch to one of three regimens involving once-weekly doses of CagriSema. The first group will switch directly to dose 1 of CagriSema, the second group will start with dose 2 then switch to dose 1, and the third group will begin with dose 3, then move to dose 2, and finally dose 1. All doses are given by subcutaneous injection once weekly. The study lasts approximately six months for each participant. During the trial, participants will be monitored for treatment-emergent adverse events from the start of treatment through week 16 and up to week 22. Assessments include checking for episodes of low blood sugar confirmed by glucose measurements and gastrointestinal side effects that may cause participants to stop treatment. Participants will have regular visits to track safety and tolerability while receiving the study drug. The overall study duration for participants is about six months.

Age: 18Years +All GendersPhase 3
40 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the impact of telehealth self-management coaching sessions on the quality of life of pancreatic cancer survivors and their family caregivers. Pancreatic cancer patients often face numerous symptoms from the disease and its treatment, which can negatively affect their quality of life. This study aims to address unmet needs by providing support in managing physical symptoms, emotional, social, and spiritual well-being through remote coaching. Participants will be divided into two groups one group will attend telehealth self-management coaching sessions lasting 40 to 60 minutes every other week for a total of six sessions over three months. The other group will receive standard care. Both patients and their family caregivers are included in the coaching sessions, which are designed to help with symptom management and caregiver support. During the study, participants will complete questionnaires to report on quality of life, symptom severity, psychological distress, caregiving burden, and overall survival. These assessments occur at the start of the study and at 3 and 6 months after randomization. The study monitors enrollment, session completion, participant experiences, and follow-up rates over up to six months, with the total study duration lasting three months for the coaching sessions and follow-up assessments continuing thereafter.

Age: 18Years +All GendersPhase Not Applicable
22 locations